The European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has recommended extending the use of the prostate cancer pill abiraterone acetate Zytiga, Janssen to include men with advanced prostate cancer who fail on androgen-deprivation therapy.The drug is currently approved in Europe and the United States for these same men, but only as second-line treatment, after docetaxel chemotherapy. If approved, abiraterone could be used by European clinicians as a first-line treatment for men who progress on androgen-deprivation therapy.Specifically, CHMP recommended that abiraterone be administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer mCRPC who are asymptomatic or mildly symptomatic after the failure of androgen-deprivation therapy.
via Europe Gives Nod to Prostate Cancer Pill Before Chemo.
Abiraterone is a well tolerated oral medication that currently has been FDA approved in the treatment of men with advanced (metastatic castrate resistant prostate cancer {mCRPC}) prostate cancer who have received previous chemotherapy containing docetaxel. This indication is being sought in the US as well.